Page 98 - 《中国药房》2025年5期
P. 98

·药学服务·


          临床药师参与1例重症恙虫病致混合性休克的药学实践                                                              Δ


                                      3
                                              3 #
                            1, 2
          黄小艳    1, 2* ,谢静文 ,夏延哲 ,李 佳 (1.中山大学附属第六医院药学部,广州 510655;2.广州市黄埔区中
          六生物医学创新研究院,广州 510655;3.中山大学附属第一医院药学部,广州 510080)
          中图分类号  R969.3      文献标志码  A      文章编号  1001-0408(2025)05-0600-06
          DOI  10.6039/j.issn.1001-0408.2025.05.17


          摘   要  目的  为重症恙虫病患者的抗感染方案调整、不良反应识别及个体化药学监护提供参考。方法  临床药师参与1例重症
          恙虫病致混合性休克并行连续性肾脏替代治疗及体外膜肺氧合的患者抗感染的药学监护过程。患者初始给予美罗培南(1 g,
          q12 h,ivdrip)联合多西环素(0.1 g,q12 h,po)治疗,因其肠道功能差,后改为美罗培南(1 g,q8 h,ivdrip)联合奥马环素(100 mg,qd,
          ivdrip)治疗。患者情况逐渐变差,感染未受控制,临床药师建议临床医生将抗感染方案调整为美罗培南(2 g,q8 h,ivdrip)联合替
          加环素(100 mg首剂;50 mg,q12 h维持;ivdrip)。临床医生采纳临床药师的建议。治疗后患者症状好转,感染指标明显下降,感染受
          控。但因患者胆红素持续上升,为减少药物性肝损伤风险,临床药师建议临床医生可将替加环素替换为阿奇霉素(0.5 g,qd,ivdrip)。
          结果  治疗后肺泡灌洗液及血标本宏基因组高通量测序提示患者恙虫病东方体被完全清除。结论  替加环素是重症恙虫病患者的
          一个有效选择。对于极危重的恙虫病患者,采用替加环素联合阿奇霉素治疗可能是清除恙虫病东方体更有效的方案。
          关键词  恙虫病;脓毒症休克;心源性休克;替加环素;阿奇霉素;药学监护;危重症

          Practice  of  clinical  pharmacist  participating  in  the  treatment  of  a  case  of  mixed  shock  caused  by  severe
          scrub typhus
          HUANG Xiaoyan ,XIE Jingwen ,XIA Yanzhe ,LI Jia(1. Dept. of Pharmacy, the Sixth Affiliated Hospital of
                                                            3
                                                     3
                                        1, 2
                          1, 2
          Sun  Yat-sen  University,  Guangzhou  510655,  China;2.  Guangzhou  Huangpu  District  Zhongliu  Institute  for
          Biomedical  Innovation,  Guangzhou  510655,  China;3.  Dept.  of  Pharmacy,  the  First Affiliated  Hospital  of  Sun
          Yat-sen University, Guangzhou 510080, China)

          ABSTRACT    OBJECTIVE  To  provide  valuable  insights  for  the  adjustment  of  anti-infectious  regimens,  identification  of  adverse
          reactions,  and  individualized  pharmaceutical  care  in  patients  with  critically  severe  scrub  typhus.  METHODS  Clinical  pharmacists
          actively  participated  in  the  pharmaceutical  care  process  for  a  patient  with  severe  scrub  typhus  leading  to  mixed  shock  undergoing
          continuous  renal  replacement  therapy  and  extracorporeal  membrane  oxygenation.  Initially,  the  patient  received  meropenem (1  g,
          q12 h, ivdrip), in combination with doxycycline (0.1 g, q12 h, po), which was later switched to meropenem (1 g, q8 h, ivdrip)
          along  with  omacycline (100  mg,  qd,  ivdrip)  due  to  impaired  gastrointestinal  function.  However,  as  the  patient’s  condition
          progressively deteriorated and the infection became uncontrolled, the clinical pharmacists recommended that the clinicians adjust the
          anti-infective  regimen  to  meropenem (2  g,  q8  h,  ivdrip)  combined  with  tigecycline (100  mg  for  first  dose;  50  mg,  q12  h  for
          maintenance;  ivdrip).  The  clinicians  followed  the  advice  of  the  clinical  pharmacists.  After  treatment,  the  patient’s  symptoms
          exhibited  significant  improvement,  accompanied  by  a  notable  decrease  in  inflammatory  markers,  indicating  that  the  infection  had
          been  successfully  controlled.  However,  due  to  continuously  increasing  bilirubin  levels,  in  order  to  reduce  the  risk  of  drug-induced
          liver  injury,  the  clinicians  changed  tigecycline  to  azithromycin (0.5  g,  qd,  ivdrip)  following  the  recommendation  of  the  clinical
          pharmacists.  RESULTS  Ultimately,  metagenomic  next-generation  sequencing  of  the  bronchoalveolar  lavage  fluid  and  blood
          specimens  indicated  that  Orientia  tsutsugamushi  had  been  completely  eradicated  in  the  patient.  CONCLUSIONS  Tigecycline  may
          be  a  viable  therapeutic  choice  for  patients  with  severe  scrub  typhus.  In  the  context  of  critically  ill  patients  with  scrub  typhus,
                                                              combining  tigecycline  with  azithromycin  might  potentially
              Δ  基金项目 广 东 省 医 院 协 会 医 院 药 学 科 研 专 项(No.
                                                              enhance the efficacy in eliminating Orientia tsutsugamushi.
          YXKY202212);广东省药学会科学研究基金立项项目(No.2023KJ20)
             *第一作者 主管药师,硕士。研究方向:临床药学。E-mail:                  KEYWORDS    scrub  typhus;  septic  shock;  cardiogenic
          huangxy278@mail.sysu.edu.cn                         shock;  tigecycline;  azithromycin;  pharmaceutical  care;
              # 通信作者 副主任药师,硕士。研究方向:临床药学。E-mail:               critically ill
          lijia37@mail.sysu.edu.cn


          · 600 ·    China Pharmacy  2025 Vol. 36  No. 5                               中国药房  2025年第36卷第5期
   93   94   95   96   97   98   99   100   101   102   103